and significant negative correlation between both markers and serum albumin (r=-0.4, P<0.001 and r=-0.5, P<0.0001 respectively) and significant negative correlation between both markers and hemoglobin levels (r=-0.8, P< 0.0001 and r=-0.8, P< 0.0001 respectively 
INTRODUCTION
It has long been known that among patients with chronic renal failure, cardiac disease was the single greatest cause of mortality, accounting for nearly one half of all deaths
(1) . Among community-based population, renal insufficiency was an independent predictor of the risk of subsequent ischemic heart disease, conferring a risk equivalent to that of diabetes (2) . Furthermore, the presence of even moderate renal impairment in a patient presenting with an acute coronary syndrome was strong shortterm prognostic indicator, significantly increasing the 30-day risk of myocardial infarction, heart failure, and cardiac death (3) . Thus, a strong and pervasive link clearly exists between kidney failure and cardiac disease. The common challenge to the nephrologists and cardiologist therefore lies in successfully recognizing those patients within their scope of practice who are most at risk, thereby allowing targeted application of interventions designed to circumvent adverse outcomes (4) . A variety of individual biomarkers have been evaluated to predict adverse events among patients with various degrees of kidney dysfunction. These included markers of ventricular dysfunction as B-type natriuretic peptide (BNP) and markers of systemic inflammation as high sensitivity C-reactive protein (hsCRP) (5) . BNP had recently gained a great deal of attention, not only for their clear diagnostic value in patients with heart failure but, also, as tools for risk stratification in patients with suspected acute coronary syndrome (4) . Patients receiving hemodialysis are usually exposed to increased peripheral vascular resistance and volume abnormalities and, thus, chronically increased ventricular afterload, significant increase in the level of BNP (4) and (6) . Also, expansion of extra-cellular volume causing myocardial stretching and increased left ventricular pressures, which is the principal cause of increased level of BNP. The left ventricular hypertrophy and endothelial dysfunction in severe chronic renal failure, systolic and diastolic dysfunction, the associated cardiac disease (usually ischaemic), also contribute to that increase (7) . hsCRP was considered to be the prototype marker of inflammation. In the general population, there were ample clinical and epidemiological data that indicate its usefulness both in predicting the prognosis for various forms of cardiovascular and renal disease and in monitoring response to treatment. There was, also, evolving evidence that hsCRP may be directly involved in the pathological disease process itself (8) . In patients with chronic renal failure, increased level of hsCRP was accounted for both traditional and non-traditional risk factors. However, since it is a nonspecific inflammatory marker and acute phase reactant, hsCRP may become elevated as a result of other dialysis-related and dialysateunrelated factors (8) . Erythrocyte sedimentation rate (ESR) was widely used in the general population. It can be used in heamodialysis patients much in the same way as in general population, as it was influenced by the same factors (9) . 
Aim of the Work

PATIENTS & METHODS
Patients:
The present study was carried out on 38 patients with chronic renal failure and 15 age and sex matched healthy controls. Venous blood samples were withdrawn from venous end of an AV fistula at the beginning of the hemodialysis session. Each blood sample was divided into two halves. One half was collected in a tube containing K 2 EDTA and immediately centrifuged in 500 rpm for 15 minutes. The separated plasma was stored at -70°C until measurement of BNP and hsCRP. The second half was allowed to clot at room temperature and centrifuged at 500 rpm for 10 min. The serum was collected and stored at -70°C and used for determination of urea, creatinine and albumin. Urine Sampling:
Urine was collected in plastic container and stored in a refrigerator at 4°C until the estimation of urinary albumin.
Biochemical measurement:
The Ultrasonography to the kidney was performed to all patients and any abnormalities were recorded. The severity of renal affection was assessed by renal echogenisity according to the grading that was described by Rosenfield et al., (17) .
Statistical analysis:
It was performed using SPSS statistical program (statistical package for social science, version 11) for analyzing the resulted data. All the studied parameters concentrations were presented as mean ±SD. The one-way ANOVA was used to determine the significance of the difference between the groups. Student t-test was used to compare between two groups. Qualitative data were presented in the form of number and percentage. Chi-square test was used to compare between qualitative data and Pearson correlation coefficient to study the relation between variables. P-value < 0.05 was considered significant.
RESULTS
In the present study, the patients were divided into five groups according to the renal echogenisity assessed by ultrasonography. Group 1 with grade 0 (n=3, 7.9%), group 2 with grade I (n=2, 5.3%), group 3 with grade II (n=15, 39.5%), group 4 with grade III renal echogenisity (n=14, 36.8%) and group 5 with complete loss of the medulla and cortex of the kidney (n=4, 10.5%).
The baseline clinical characteristics of the patients and controls are presented in (Table 1) . The patients and controls were similar for distribution of age and gender. In particular, higher percent of patients had hypertension and diabetes mellitus. Patients had significantly higher values of blood urea 40.4±11.3 mmol/L, higher value of serum creatinine 1133.4±397.0 umol/L, lower value of serum albumin 36.3±6.6 gm/L, lower value of hemoglobin 7.7±1.3 g/dl (p<0.0001 for each) ( Table 2 ). Albumin detected in the urine of patients and there were 6 patients with no albumin in urine, 17 patients with (+) urinary albumin, 12 patients with (++) urinary albumin and 3 patients with (+++) urinary albumin. In addition patients had significantly higher value of the ESR in the first and second hours than controls, 67.9±21.3 mm and 90.1±24.4 mm respectively ( p<0.0001 for each) ( Table 3) .
The mean plasma levels of BNP and hsCRP were 274.3±97.1 pg/ml and 11.4±3.9 mg/L in patients and 33.7±8.0 pg/ml and 2.7±1.0 mg/L in controls. It was clear that the plasma levels of both markers were significantly higher in patients than controls (p< 0.0001for each) (Table  3) .
In the present study, also, plasma levels of BNP and hsCRP were compared with ultrasonograghic renal echogenisity in patients with chronic renal failure. The plasma mean levels of BNP were 104.7±15.0 pg/ml, 148.0±67.9 pg/ml, 248.5±72.0 pg/ml, 310.1±39.2 pg/ml and 436.0±10.0 pg/ml in patients with grade 0, grade I, grade II, grade III renal echogenisity and patients with complete loss of the medulla and cortex respectively. hsCRP were 4.7±0.6 mg/L, 5.5±0.7 mg/L, 10.3±3.2 mg/L, 13.6±1.8 mg/L and 16.0±0.8 mg/L in the same previous groups respectively. The plasma levels of both biomarkers were significantly higher in patients with more severe renal affection (Table 4 and 5).
There was highly significant positive correlation between plasma levels of BNP and hsCRP in all groups of patients (r=0.9, P< 0.0001) (figure 1). Also there was highly significant negative correlation between plasma levels of BNP and hsCRP with serum albumin (r=-0.4, P<0.001 and r=-0.5, P<0.0001 respectively), highly significant negative correlation between both markers and Hb levels (r=-0.8, P<0.0001 and r= 0.8, P< 0.0001 respectively) and highly positive correlation with urea, creatinine levels and ESR in both first and second hours. There was significant positive correlation between the levels of BNP and hsCRP and the degree of renal echogenisity that detected by ultrasonography and reflect severity of renal affection (r= 0.8, P< 0.001 and r= 0.9, P< 0.001 respectivily). 
40.4 ±11.3 1133.4 ± 397.0 36.3 ± 6.6 7.7 ± 1.3 5.9 ± 0.6 121.3 ± 6.7 49.7 ± 4.6 14.2 ± 1.2 P< 0.0001 P< 0.0001 P< 0.0001 P<0.0001 . In addition, it has emerged as a biomarker for altered myocardial function and structure and it has been shown to be increased in patients with renal insufficiency and reflect cardiac preload and afterload as well as intrinsic heart disease, thus providing an index of cardiac stress. Furthermore, circulating BNP levels are predictive of cardiovascular outcome in ESRD patients (22) . In the present study, a significant increase in the mean plasma levels of BNP in patients with chronic renal failure before dialysis was found than in control. This result was in agreement with that of Apple et al. (34) who found that ESR could be useful in diagnosing of inflammation in hemodialysis patients as it was increased in patients with chronic renal failure and correlated positively with CRP and inversely with serum albumin. Also, Brouillard et al. concluded that ESR was increased in most of patients with chronic renal failure.
There was significant positive correlation between plasma levels of BNP and hsCRP with the severity of renal involvement that was detected by ultrasonography. Fred et al.
(29) and Anwaruddin et al. (27) found a significant inverse relationship between renal function and BNP in patients with chronic renal failure. Also, Codoqnotto et al. (35) found that BNP and hsCRP were increased in patients with uremia and there was inverse relationship between the plasma levels of both markers and glomerular filtiration rate. On the other hand, Zoccali.
(22) found that hsCRP was unrelated to GFR and progression of disease. This lack of association does not necessary imply a lack of causation. Indeed circulating hsCRP may be inadequate marker of the severity of renal inflammation. In that regards, it was noting that other markers as BNP were apparently useful for monitoring progression of renal disease (22) . The relationship between plasma levels of BNP and hsCRP with the severity of renal affection, which was detected by degree of ultrasonographic echogenisity were not studied by several researchers and need progressive studies.
In the present study there was a highly significant positive correlation between plasma levels of BNP and hsCRP and highly significant negative correlation between the previous two parameters with serum albumin and Hb levels. This results was in agreement with that of Ortega et al. who found that the correlation between BNP and hsCRP was stronger in predialysis patients and both parameters were inversely correlated with creatinine clearance, serum albumin and Hb levels. It is important to note that the combination of two biomarker, hsCRP and BNP was almost informative and these biomarkers, at least, in part, reflect overlapping pathologic processes. Also, they possess the major characteristics required for a marker to be recommended for wide use in clinical practice, namely, they should provide independent information in risk or prognosis beyond established risk factors and they should be easy to measure (37) . Recently completed and ongoing trials will provide specific answers to the hypothesis that BNP and hsCRP might be a guide to treatment in ESRD patients (20) . If positive, these trials will constitute a definitive argument for the widespread use of these biomarkers in the dialysis populations. In the specific case of ESRD, BNP and hsCRP may, also, have other practical implications because the measurement of circulating levels of these substances may be useful also for comparing the cardiovascular burden of diverse dialysis populations (20) .
Conclusion:
The present results suggest a link between left ventricular pressure and inflammation in patients with chronic renal failure. The importance of strict volume control in these patients, in order to reduce left ventricular pressure and therefore inflammation, should be considered. The combination of the two biomarkers were to identify patients at particularly high risk and identify a potential role for these biomarkers to be incorporated into diagnostic and therapeutic strategies aimed at detection and treatment of atherosclerotic complications. 
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